ARS Pharmaceuticals, Inc. SPRY Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s change in deferred revenue?
- ARS Pharmaceuticals, Inc. (SPRY) reported change in deferred revenue of -$61K in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s change in deferred revenue changed year-over-year?
- ARS Pharmaceuticals, Inc.'s change in deferred revenue increased by 71.0% year-over-year, from -$210K to -$61K.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s change in deferred revenue?
- Over 3 years (2021 to 2025), ARS Pharmaceuticals, Inc.'s change in deferred revenue has grown at a -48.1% compound annual growth rate (CAGR), from -$2.51M to -$350K.
- What does change in deferred revenue mean?
- Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.